Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance

Río-Vilariño, Anxo; Puerto‐Nevado, Laura del; García‐Foncillas, Jesús; Cebrián, Arancha

doi:10.3390/cancers13153757

Cited by 3 publications

(1 citation statement)

References 192 publications

(200 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Colorectal cancer usually requires the surgical removal of tumor tissue, chemotherapy and targeted therapy. At present, new targeted drugs are mainly aimed at the tumor angiogenesis endothelial growth factor (vascular endothelial growth factor, VEGF) and receptor (vascular endothelial growth factor receptor, VEGFR), or the epidermal growth factor receptor (EGFR) (Rio-Vilariño et al, 2021). However, more than 30% of cases are resistant to EGFR inhibitors, so it is crucial to find new therapeutic targets (Mangiapane et al, 2022).…”

Section: Summary and Future Perspectivementioning

confidence: 99%

MicroRNAs Are Key Molecules Involved in the Gene Regulation Network of Colorectal Cancer

Yang

Xuan

Chen

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common types of cancer and one of the leading causes of mortality worldwide. MicroRNAs (miRNAs) play central roles in normal cell maintenance, development, and other physiological processes. Growing evidence has illustrated that dysregulated miRNAs can participate in the initiation, progression, metastasis, and therapeutic resistance that confer miRNAs to serve as clinical biomarkers and therapeutic targets for CRC. Through binding to the 3′-untranslated region (3′-UTR) of target genes, miRNAs can lead to target mRNA degradation or inhibition at a post-transcriptional level. During the last decade, studies have found numerous miRNAs and their potential targets, but the complex network of miRNA/Targets in CRC remains unclear. In this review, we sought to summarize the complicated roles of the miRNA-target regulation network (Wnt, TGF-β, PI3K-AKT, MAPK, and EMT related pathways) in CRC with up-to-date, high-quality published data. In particular, we aimed to discuss the downstream miRNAs of specific pathways. We hope these data can be a potent supplement for the canonical miRNA-target regulation network.

show abstract

Section: Summary and Future Perspectivementioning

confidence: 99%

MicroRNAs Are Key Molecules Involved in the Gene Regulation Network of Colorectal Cancer

Yang

Xuan

Chen

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer

Li,

Wang,

Yang

et al. 2024

Nat Commun

View full text Add to dashboard Cite

Cetuximab therapy is the major treatment for colorectal cancer (CRC), but drug resistance limits its effectiveness. Here, we perform longitudinal and deep proteomic profiling of 641 plasma samples originated from 147 CRC patients (CRCs) undergoing cetuximab therapy with multi-course treatment, and 90 healthy controls (HCs). COL12A1, THBS2, S100A8, and S100A9 are screened as potential proteins to distinguish CRCs from HCs both in plasma and tissue validation cohorts. We identify the potential biomarkers (RRAS2, MMP8, FBLN1, RPTOR, and IMPDH2) for the initial response prediction. In a longitudinal setting, we identify two clusters with distinct fluctuations and construct the model with high accuracy to predict the longitudinal response, further validated in the independent cohort. This study reveals the heterogeneity of different biomarkers for tumor diagnosis, the initial and longitudinal response prediction respectively in the first course and multi-course cetuximab treatment, may ultimately be useful in monitoring and intervention strategies for CRC.

show abstract

Fragment-based Drug Discovery Successful Contributions to Current Pharmacotherapeutic Agents Arsenal against Aggressive Cancers: A Mini-Review

Santos

Silveira

2023

ACAMC

View full text Add to dashboard Cite

After a decade of approval of the drug vemurafenib in 2011, the hopeless scenario imposed by some severe cancer types has been mitigated by the magic bullets developed through fragment-based drug discovery. Moreover, this recent approach to medicinal chemistry has been successfully practiced by academic laboratories and pharmaceutical industry workflows focused on drug design with an enhanced profile for chemotherapy of aggressive tumors. This mini-review highlights the successes achieved by these research campaigns in the fruitful field of the molecular fragment paradigm that resulted in the approval of six new anticancer drugs in the last decade (2011-2021), as well as several promising clinical candidates. It is a particularly encouraging opportunity for other researchers who want to become aware of the applicability and potency of this new paradigm applied to the design and development of powerful molecular weapons in the constant war against these merciless scourges of humanity.

show abstract

Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance

Cited by 3 publications

References 192 publications

MicroRNAs Are Key Molecules Involved in the Gene Regulation Network of Colorectal Cancer

MicroRNAs Are Key Molecules Involved in the Gene Regulation Network of Colorectal Cancer

Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer

Fragment-based Drug Discovery Successful Contributions to Current Pharmacotherapeutic Agents Arsenal against Aggressive Cancers: A Mini-Review

Contact Info

Product

Resources

About